OmniAb, Inc. (NASDAQ:OABI) held its first Research & Technology virtual event, where it launched OmnidAb, a platform for single domain antibodies based on a human VH scaffold that matures in a chicken host environment. The company also discussed OmniDeep, a suite of in silico tools for therapeutic discovery and optimization that uses artificial intelligence and machine learning. OmniAb's ion channel technologies, which have collaborations with GSK and Roche, were also highlighted.